Evolus Inc Stock
€7.85
Your prediction
Evolus Inc Stock
Pros and Cons of Evolus Inc in the next few years
Pros
Cons
Performance of Evolus Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Evolus Inc | -2.480% | 1.290% | -7.647% | -27.982% | -25.238% | -36.694% | 176.701% |
| Krystal Biotech | -0.970% | 6.921% | 7.326% | -33.115% | -16.261% | 74.589% | - |
| Ardelyx Inc. | -0.430% | 1.307% | 21.087% | -28.959% | -21.934% | 462.065% | -28.881% |
| Champions Oncology Inc | -7.530% | -8.784% | 9.756% | 47.380% | 41.807% | -11.184% | -11.765% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon an initial overview of the financials of Evolus Inc. (EOLS), a bio-tech and medical research company, it's evident that there are both strong and weak points to consider. Considering the financial data spanning across the past three fiscal years, including some quarterly numbers in 2023, it draws a multifaceted financial landscape.
A positive aspect gleaned from the company's income statements is a rising gross profit margin, growing from $38.2 million in 2020 to $92.7 million in 2022. This amplification reflects the company's ability to effectively manage costs related to goods sold, marking a positive trend in cost efficiency.
Though the company's retained earnings have been in a deficit, indicating more accumulated losses than profits, it's important to reference the pattern of decreasing net losses from a drastic -$163 million in 2020 to a lesser -$74.4 million by 2022. This trajectory proposes that the company's strategy in minimizing losses is at least cursorily effective.
Comments
News
Evolus Stock: Executives Sell Shares Amid Strong Growth
In March 2025, several top executives at healthcare company Evolus sold significant portions of their company shares through pre-established 10b5-1 trading plans. Director David Moatazedi divested
